002370.SZ
亚太药业
SZSE · Healthcare · C 制造业 · CN
CNY 5.45
−3.71%Year over year
Reported trailing growth
- Revenue
- -10.9%
- EBITDA
- —
- EBIT
- +309.8%
- EPS
- +196.1%
- Free cash flow
- -59.3%
- Operating cash flow
- -46.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.7%
- EBITDA
- +87.3%
- EBIT
- +221.5%
- Net income
- +181.3%
- EPS
- +160.0%
- Free cash flow
- +82.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026